Table 2 Patient status and treatments received at or after enrollment
From: Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Variables | Total patients (n = 41) | hUC-MSC (N = 12) | Control (N = 29) | P value |
|---|---|---|---|---|
NEWS2 score at day 1-median (IQR) | 8.00 (7.00, 10.00) | 9.0 (8.00, 10.75) | 8.00 (7.00, 10.00) | 0.098 |
Seven-category scale at day 1 | ||||
 3: Hospitalization, not requiring supplemental oxygen, No. (%) | 3 (7.31%) | 1 (8.33%) | 2 (6.90%) | 1.000 |
 4: Hospitalization, requiring supplemental oxygen, No. (%) | 28 (68.30%) | 7 (58.33%) | 21(72.41%) | 0.469 |
 5: Hospitalization, requiring HFNC or noninvasive mechanical ventilation, No. (%) | 10 (24.39%) | 4 (33.33%) | 6 (20.69%) | 0.441 |
 6: Hospitalization, requiring ECMO, invasive mechanical ventilation, or both, No. (%) | 0 | 0 | 0 | 1.000 |
 Days from illness onset to randomization median (IQR) | 13.00 (9.00, 17.50) | 11.50 (6.00, 20.00) | 14.00 (10.00, 18.00) | 0.135 |
 Earlier (≤ 12 days of symptom onset), No. (%) | 17 (41.46%) | 7 (58.33%) | 10 (34.48%) | 0.184 |
 Later (> 12 days of symptom onset), No. (%) | 24 (58.54%) | 5 (41.67%) | 19 (65.52%) | 0.184 |
Treatments during study period, No. (%) | ||||
 Noninvasive mechanical ventilation | 5 (12.20%) | 3 (25%) | 2 (6.70%) | 0.139 |
 Invasive mechanical ventilation | 4 (9.76%) | 0 | 4 (13.79%) | 0.302 |
 Antibiotic agent | 36 (87.80%) | 10 (83.33%) | 26 (89.66%) | 0.620 |
 Antiviral treatment | 41 (100%) | 12 (100%) | 29 (100%) | 1.000 |
 Vasopressors | 7 (17.07%) | 0 | 7 (24.14%) | 0.085 |
 Renal-replacement therapy | 0 | 0 | 0 | 1.000 |
 ECMO | 0 | 0 | 0 | 1.000 |
 Glucocorticoid therapy | 41 (100%) | 12 (100%) | 29 (100%) | 1.000 |
 Days of glucocorticoid therapy-median (IQR) | 5.00 (3.00, 8.50) | 7.50 (5.00, 9.75) | 5.00 (3.50, 9.00) | 0.195 |